Why I think the Sonic Healthcare share price is a buy

Here are three reasons.

| More on:
Two happy scientists analysing test results.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Key points

  • At their beaten-down price, I think Sonic Healthcare shares present an opportunity
  • The healthcare company is still growing revenue, including with its core operations
  • Sonic has been making acquisitions to boost its business and improve its growth outlook

The Sonic Healthcare Ltd (ASX: SHL) share price has seen plenty of volatility over the last two and a half years.

Adding its 20% decline in 2022 to the equation, I believe that the company's beaten-down share price now offers compelling value.

Sonic Healthcare has medical diagnostic operations in several countries including Australia, the United States, Germany, the United Kingdom, Switzerland, Belgium and New Zealand. It also has clinical services and a growing radiology division.

A pathology business may sound a little boring, but I think there's plenty to be excited about. Here are three reasons why I think Sonic Healthcare is an attractive long-term opportunity.

1. Acquisitions

The company has made a number of acquisitions in recent times, which I think will unlock longer-term growth for the ASX healthcare share.

In the FY22 first half, Sonic Healthcare put $585 million into acquisitions and investments.

That includes the ProPath acquisition in Dallas, Texas, which added US$110 million of revenue. The Canberra Imaging Group deal added A$60 million of revenue to the business.

It also invested in Harrison.ai for a 20% stake and established a pathology joint venture.

Sonic says that artificial intelligence has significant potential to enhance diagnostic accuracy, reproducibility and efficiency in pathology and radiology.

The company added that its deep clinical expertise, combined with Harrison.ai's proven AI methodologies, were set to create a "powerful force" in healthcare AI.

2. Ongoing core revenue growth

In my opinion, one of the more important things that a business needs to be able to deliver good investment returns is decent revenue growth. It's hard to grow profit if revenue isn't rising.

Sonic Healthcare has benefited from high volumes of COVID-19 testing. But base revenue in the FY22 first half also rose by 4.3% year on year. Management is expecting ongoing growth of the base business, with "strong" underlying drivers, including a catch-up of testing postponed because of the COVID-19 pandemic.

Growth of the base business will help the core net profit after tax (NPAT) rise over time.

Sonic Healthcare has used its COVID testing cash windfall to make acquisitions and launch a share buy-back.

However, the ASX share is also expecting a sustainable level of COVID testing in the future including "routine COVID-19 testing, screening programs, variant testing, whole-genome sequencing, [and] antibody tests".

There are still many thousands of PCR tests being done in Australia, although Sonic is not responsible for all of them. For example, New South Wales reported that 30,006 PCR tests were conducted in the 24 hours prior to 4pm on 1 June 2022.

3. Dividends

While Sonic Healthcare's dividend yield is not exactly huge, its progressive dividend policy means that the dividend is steadily growing.

The trailing dividend yield is 2.6% at the current Sonic Healthcare share price, excluding the effect of franking credits.

In my opinion, an ASX share that pays dividends can usually offer a handy boost for returns for shareholders.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three people in a corporate office pour over a tablet, ready to invest.
Broker Notes

Bell Potter just slapped a buy on this ASX 200 share offering a 30% return

Which stock is being tipped as a buy? Let's find out.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Macquarie initiates coverage of Neuren Pharmaceuticals shares; forecasts 45% upside

The broker described Neuren as a standout in the ASX biotech sector.

Read more »

A woman leans forward with her hand behind her ear, as if trying to hear information.
Healthcare Shares

Does Macquarie think Cochlear shares are a buy, hold, or sell?

Macquarie has released a new note on Cochlear following the company's FY25 profit guidance change.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

Up 18% this year, does Macquarie expect NIB shares to go higher?

This expert has a bold prediction for NIB.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why is the Mesoblast share price up 11% in June?

The ASX biotech share reached a 10-week high of $1.94 today.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Up 51% since the tariff pain, is it too late to buy Pro Medicus shares?

After rocketing higher, is the ASX healthcare share still an opportunity?

Read more »

A woman wearing a yellow shirt smiles as she checks her phone.
Healthcare Shares

CSL shares push higher on US FDA approval

This biotech giant has been given a boost in the United States.

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Up 29% this year, does Macquarie expect Medibank Private shares to continue rising?

Medibank's explosive share price growth has caught the eye of this broker.

Read more »